116 related articles for article (PubMed ID: 36456131)
1. Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma.
Morishita Y; Takenouchi K; Sakashita S; Matsuura K; Hayashi R; Nakatsura T
Anticancer Res; 2022 Dec; 42(12):5751-5761. PubMed ID: 36456131
[TBL] [Abstract][Full Text] [Related]
2. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP
Front Immunol; 2021; 12():763086. PubMed ID: 34733290
[TBL] [Abstract][Full Text] [Related]
3. Personalized cancer vaccination in head and neck cancer.
Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
[TBL] [Abstract][Full Text] [Related]
4. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.
Vora AR; Rodgers S; Parker AJ; Start R; Rees RC; Murray AK
Br J Cancer; 1997; 76(7):836-44. PubMed ID: 9328140
[TBL] [Abstract][Full Text] [Related]
6. HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients.
Wichmann G; Herchenhahn C; Boehm A; Mozet C; Hofer M; Fischer M; Kolb M; Dietz A
Oral Oncol; 2017 Jun; 69():115-127. PubMed ID: 28559015
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
Baysal H; Siozopoulou V; Zaryouh H; Hermans C; Lau HW; Lambrechts H; Fransen E; De Pauw I; Jacobs J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; De Waele J; Wouters A
Front Immunol; 2022; 13():1001161. PubMed ID: 36268020
[TBL] [Abstract][Full Text] [Related]
8. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune-related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma.
Li Q; Shen Z; Shen Y; Deng H; Shen Y; Wang J; Zhan G; Zhou C
J Clin Lab Anal; 2022 Jun; 36(6):e24484. PubMed ID: 35561269
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
11. HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites.
Mattijssen V; De Mulder PH; Schalkwijk L; Manni JJ; Van 't Hof-Grootenboer B; Ruiter DJ
Int J Cancer Suppl; 1991; 6():95-100. PubMed ID: 2066187
[TBL] [Abstract][Full Text] [Related]
12. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis.
Bandoh N; Ogino T; Katayama A; Takahara M; Katada A; Hayashi T; Harabuchi Y
Oncol Rep; 2010 Apr; 23(4):933-9. PubMed ID: 20204276
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
15. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
[TBL] [Abstract][Full Text] [Related]
16. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
17. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
[TBL] [Abstract][Full Text] [Related]
19. Influence of Photodynamic Therapy on the Expression of Cancer/Testis Antigens in Squamous Cell Carcinoma of the Head and Neck.
Theodoraki MN; Lorenz KJ; Schneider J; Thierauf JC; Spagnoli G; Schuler PJ; Hoffmann TK; Laban S
Anticancer Res; 2016 Aug; 36(8):3973-82. PubMed ID: 27466502
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
[Next] [New Search]